Table 1. Patient characteristics.
| Characteristic | Good responder | Poor responder | |
|---|---|---|---|
| Total number | 56 | 18 | |
| Median age (range) | 67 (35–75) | 63 (36–80) | 0.7099 |
| Sex | |||
| male | 32 (57%) | 6 (33%) | 0.1057 |
| female | 24 (43%) | 12 (67%) | |
| M protein | |||
| IgG | 31 (55%) | 6 (33%) | |
| IgA | 11 (20%) | 4 (22%) | |
| BJP | 13 (23%) | 5 (28%) | |
| IgD | 1 (2%) | 3 (17%) | |
| Light chain | |||
| κ | 37 (66%) | 11 (61%) | 0.7793 |
| λ | 19 (34%) | 7 (39%) | |
| β2 microglobulin | |||
| ≥ 5.5 mg/L | 23 (41%) | 9 (50%) | 0.5887 |
| Albumin | |||
| > 3.5 g/dL | 31 (55%) | 5 (28%) | 0.0582 |
| Cytogenetic/genetic aberrations | |||
| t(11;14) / CCND1 | 8 (14%) | 6 (33%) | |
| t(4;14) / FGFR3 | 12 (21%) | 5 (28%) | |
| t(14;16) / cMAF | 5 (9%) | 2 (11%) | |
| Negative for above 3 translocations | 21 (38%) | 3 (17%) | |
| Not evaluated | 10 (18%) | 2 (11%) | |
| High-risk feature† | 17 (30%) | 7 (39%) | 0.5676 |
| Prior treatment | |||
| 0 | 14 (25%) | 5 (28%) | |
| 1 | 23 (41%) | 1 (6%) | |
| 2 | 9 (16%) | 8 (44%) | |
| 3 and over | 10 (18%) | 4 (22%) | 0.7335 |
| prior IMIDs‡ | 11 (20%) | 7 (39%) | 0.1199 |
| prior PBSCT* | 18 (32%) | 5 (28%) | 1.0000 |
| Induction therapy for PBSCT* | |||
| 10 (18%) | 3 (17%) | 1.0000 | |
| Best response | |||
| CR | 4 (7%) | - | |
| VGPR | 24 (43%) | - | |
| PR | 28 (50%) | - | |
| SD | - | 15 (83%) | |
| PD | - | 3 (17%) | |
| Progression-free survival (median) | 171 days | 87.5 days | |
†High-risk feature includes the cases with t(4;14) /FGFR3 or t(14;16) /cMAF
‡ Including lenalidomide and thalidomide
*Peripheral blood stem cell transplantation